Table 5.
Subgroup analysis for pooled microRNAs in association with CRC staging and tumour location.
| miRNA | No. of Studies | AUC | Partial AUC | log DOR (95% CI) | DOR (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | +LR (95% CI) | −LR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Staging# (Based on the data from the included studies) | |||||||||
| Early | 11 | 0.753 | 0.582 | 1.72 (1.29–2.15) | 5.58 (3.62–8.62) | 57.0% (44.4–68.8%) | 80.0% (71.1–86.7%) | 2.68 (2.10–3.43) | 0.54 (0.43–0.68) |
| Late | 11 | 0.787 | 0.627 | 1.90 (1.47–2.34) | 6.70 (4.34–10.36) | 62.1% (47.8–74.6%) | 80.0% (71.1–86.7%) | 2.82 (2.22–3.59) | 0.45 (0.33–0.61) |
| Tumour location (Based on the data from the included studies) | |||||||||
| Proximal | 9 | 0.719 | 0.488 | 1.23 (0.93–1.54) | 3.44 (2.53–4.66) | 39.8% (21.8–61.0%) | 82.4% (71.5–89.7%) | 2.08 (1.76–2.44) | 0.75 (0.64–0.88) |
| Distal | 9 | 0.818 | 0.675 | 2.14 (1.60–2.68) | 8.51 (4.97–14.57) | 64.1% (43.9–80.3%) | 81.9% (71.5–89.1%) | 3.04 (2.31–4.01) | 0.41 (0.28–0.61) |
DOR, Diagnostic odds ratio; +LR, Positive likelihood ratio; −LR, Negative likelihood ratio. #Early stage CRC includes TNM stages 0 + I + II or Dukes’ stage A + B; Late stage CRC includes CRC stages III + IV or Dukes’ stage C + D.